Literature DB >> 12205041

Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes.

Oliver Werz1, Eva Bürkert, Lutz Fischer, Dagmar Szellas, David Dishart, Bengt Samuelsson, Olof Rådmark, Dieter Steinhilber.   

Abstract

5-lipoxygenase (5-LO) is the key enzyme in the biosynthesis of proinflammatory leukotrienes. Here, we demonstrate that extracellular signal-regulated kinases (ERKs) can phosphorylate 5-LO in vitro. Efficient phosphorylation required the presence of unsaturated fatty acids and was abolished when Ser-663 was mutated to alanine. In intact HeLa cells stimulated with arachidonic acid (AA), impaired 5-LO product formation was evident in cells expressing the S663A-5-LO mutant compared with cells expressing wild-type 5-LO. For Mono Mac 6 cells, priming with phorbol myristate acetate (PMA) before stimulation with ionophore was required for ERK1/2 activation and efficient 5-LO phosphorylation, in parallel with substantial AA release and 5-LO product formation. Inhibition of PKC by GF109203x or MEK1/2 by U0126 (or PD98059) abolished the 5-LO up-regulation effects of PMA. In contrast, these inhibitors failed to suppress 5-LO product formation induced by stimuli such as AA plus ionophore, which apparently do not involve the ERK1/2 pathway. Based on inhibitor studies, ERKs are also involved in AA-stimulated 5-LO product formation in PMNL, whereas a role for ERKs is not apparent in 5-LO activation induced by ionophore or cell stress. Finally, the data suggest that ERKs and p38 MAPK-regulated MAPKAPKs can act in conjunction to stimulate 5-LO by phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205041     DOI: 10.1096/fj.01-0909fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  32 in total

1.  Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury.

Authors:  Le Wu; Sen Miao; Lin-Bing Zou; Ping Wu; Hua Hao; Ke Tang; Pan Zeng; Jing Xiong; Hong-Hua Li; Qiang Wu; Lei Cai; Du-Yun Ye
Journal:  J Mol Neurosci       Date:  2012-06-03       Impact factor: 3.444

2.  Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.

Authors:  B Hofmann; C B Rödl; A S Kahnt; T J Maier; A A Michel; M Hoffmann; O Rau; K Awwad; M Pellowska; M Wurglics; M Wacker; A Zivković; I Fleming; M Schubert-Zsilavecz; H Stark; G Schneider; D Steinhilber
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid.

Authors:  Daniel Poeckel; Lars Tausch; Anja Altmann; Christian Feisst; Ute Klinkhardt; Jochen Graff; Sebastian Harder; Oliver Werz
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

4.  5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis.

Authors:  Hendrick Plante; Serge Picard; Joseph Mancini; Pierre Borgeat
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

5.  Citreorosein inhibits degranulation and leukotriene C₄ generation through suppression of Syk pathway in mast cells.

Authors:  Yue Lu; Ying Li; Yurndong Jahng; Jong-Keun Son; Hyeun Wook Chang
Journal:  Mol Cell Biochem       Date:  2012-03-01       Impact factor: 3.396

6.  Oxidative stress suppresses cysteinyl leukotriene generation by mouse bone marrow-derived mast cells.

Authors:  Ping He; Tanya Laidlaw; Akiko Maekawa; Yoshihide Kanaoka; Kongyi Xu; Bing K Lam
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

7.  5-Lipoxygenase: mechanisms of regulation.

Authors:  Olof Rådmark; Bengt Samuelsson
Journal:  J Lipid Res       Date:  2008-11-05       Impact factor: 5.922

8.  Phospholipid Ozonation Products Activate the 5-Lipoxygenase Pathway in Macrophages.

Authors:  Karin A Zemski Berry; Robert C Murphy
Journal:  Chem Res Toxicol       Date:  2016-08-03       Impact factor: 3.739

9.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

10.  Lipoxygenase pathways in Homo neanderthalensis: functional comparison with Homo sapiens isoforms.

Authors:  Pavlos Chaitidis; Susan Adel; Monika Anton; Dagmar Heydeck; Hartmut Kuhn; Thomas Horn
Journal:  J Lipid Res       Date:  2013-03-10       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.